NEWS
MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)
MindMed (NASDAQ: MNMD) has been granted a new patent by the USPTO for its MM120 (lysergide) orally disintegrating tablet (ODT) formulation. This patent, extending protection until 2041, covers the pharmaceutical formulation, manufacturing methods, and treatment applications for MM120 ODT. The formulation incorporates Catalent's Zydis® ODT technology, which MindMed believes will offer pharmacological advantages including faster absorption, improved bioavailability, and reduced gastrointestinal side effects.
MM120 is currently in clinical development for generalized anxiety disorder (GAD) and shows potential for treating other brain health disorders. MindMed holds exclusive rights to the Zydis technology for lysergide in several key markets. CEO Rob Barrow emphasized the importance of this patent in extending IP protection and highlighting the unique properties of the MM120 ODT formulation.
MM120 is currently in clinical development for generalized anxiety disorder (GAD) and shows potential for treating other brain health disorders. MindMed holds exclusive rights to the Zydis technology for lysergide in several key markets. CEO Rob Barrow emphasized the importance of this patent in extending IP protection and highlighting the unique properties of the MM120 ODT formulation.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1193Followers
74Following
8452Visitors
Follow